Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 74 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				11213 NCT00073307

Last Modified: 6/23/2008 First Published: 4/23/2005


2.		Phase III Randomized Study of Carboplatin and Paclitaxel With Versus Without Sorafenib in Patients With Unresectable Stage III or Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-E2603 E2603, NCT00110019


3.		A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				100554 EudraCT No: 2004-001773-26, SHARP, NCT00105443


4.		Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				15 and over				Pharmaceutical / Industry				11868 NCT00111020


5.		A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				11961 EudraCT 2005-005245-19, NCT00300885


6.		Phase III Study of BAY 43-9006 in Japanese Patients With Advanced Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				11721 NCT00494299

Last Modified: 12/18/2008 First Published: 8/19/2005


7.		Phase I/II Study of Sorafenib, Cetuximab, and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				JHOC-J04104 JHOC-05012408, NCI-6996, 6996, NCT00134069, UCHSC-07-0571


8.		Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				494F01 NCT00389285


9.		Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				RCC-06-102 1006-0152, NCT00448149


10.		Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				2006-005970-26 KKS / INNERE_A / NSCLC2006, NCT00473486

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute